Strategies to enhance CAR-T persistence
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse h...
Main Authors: | Yue Liu, Lingna An, Ruihao Huang, Jingkang Xiong, Haoyu Yang, Xiaoqi Wang, Xi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-11-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-022-00434-9 |
Similar Items
-
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
by: Frederik Holm Rothemejer, et al.
Published: (2023-08-01) -
Improving CAR T-Cell Persistence
by: Violena Pietrobon, et al.
Published: (2021-10-01) -
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
by: Wei Wei, et al.
Published: (2023-08-01) -
Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
by: Maria Alvanou, et al.
Published: (2023-03-01) -
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
by: Valerie Wittibschlager, et al.
Published: (2023-03-01)